Morrisville, United States
Locus Biosciences, Inc., founded in 2015, is a clinical-stage biotechnology firm that specializes in developing precision-engineered bacteriophage products. With its focus on unmet medical needs in bacterial infections and immunology, the company employs the LOCUS platform, integrating predictive artificial intelligence and automated robotics to deliver targeted phage therapies. These therapies are designed to eliminate specific pathogens while preserving the essential microbiome.
The company has demonstrated significant progress with its recent completion of the open-label portion of a Phase 2 trial for LBP-EC01, targeting uncomplicated urinary tract infections caused by drug-resistant E. coli. Strategic alliances with key partners, such as BARDA and CARB-X, underpin its innovative approach and financial stability. Investors may find Locus Biosciences' innovative techniques and supportive partnerships an attractive opportunity in the biotechnology sector.
